A Team Driving the Future of Drug Delivery
InkVivo’s team combines scientific excellence, patented technology, and patient-centric vision to create drug delivery solutions that matter.
InkVivo Technologies AG is headquartered in Lugano, Switzerland and conducts its research in collaboration with the Macromolecular Lab at ETH in Zürich.
Our Mission
InkVivo’s mission is to develop innovative, scalable drug delivery solutions that improve patient outcomes, enhance therapeutic adherence, and enable safer, more effective treatments. We aim to provide partners with technologies that extend product lifecycles, unlock new intellectual property, and accelerate development.
Our Vision
We envision a future where InkVivo’s technology is a cornerstone of patient-centric therapies, enabling treatments tailored to individual needs and improving outcomes on a global scale. By combining scientific excellence, strategic partnerships, and advanced polymeric platforms, we aim to transform drug delivery, set new benchmarks for therapeutic innovation, and make precision medicine widely accessible.
Our history
2025 - Pre-Seed round
InkVivo successfully completed its pre-seed funding round of CHF 1.1 Millions, providing the capital to advance its proprietary drug delivery platform, expand R&D efforts, and accelerate strategic partnerships with pharmaceutical and nutraceutical companies.
2024 - Gastro-retentive patent filed & Partnerships
Patent filed for gastro-retentive drug delivery system, enabling enhanced oral drug absorption.
Strategic partnerships are signed for co-development of advanced delivery systems.
2023 - Incorporation
InkVivo Technologies SA is incorporated in Switzerland and sets headquartiers at the USI Startup Centre in Lugano.
2022 - Patents & key pubblications
Patents granted for crosslinkable hydrogel compositions
Publications in Adv Mater and Adv Healthc Mater on polymeric nanomatrix platforms.
2022 - Eccellenze Ticinesi
InkVivo is featured in the program of Swiss National Television “Eccellenze Ticinesi”
2021 - Advanced Biomaterial Research
Breakthroughs in polymer-nanoparticle hydrogels and nanomatrix biomatrices for controlled drug delivery.
InkVivo is awarded the BoldBrain Startup Challenge
2019 - First publication
Published “Universal Nanocarrier Ink Platform for Biomaterials Additive Manufacturing” in Small.
2017 - Begin of research
Research activities start as part of Elia Guzzi’s PhD.
2025 – Pre-Seed round
InkVivo successfully completed its pre-seed funding round of CHF 1.1 Millions, providing the capital to advance its proprietary drug delivery platform, expand R&D efforts, and accelerate strategic partnerships with pharmaceutical and nutraceutical companies.
2024 – Gastro-retentive patent filed & Partnerships
Patent filed for gastro-retentive drug delivery system, enabling enhanced oral drug absorption.
Strategic partnerships are signed for co-development of advanced delivery systems.
2023 – Incorporation
InkVivo Technologies SA is incorporated in Switzerland and sets headquartiers at the USI Startup Centre in Lugano.
2022 – Patents & key pubblications
Patents granted for crosslinkable hydrogel compositions
Publications in Adv Mater and Adv Healthc Mater on polymeric nanomatrix platforms.
2022 – Eccellenze Ticinesi
InkVivo is featured in the program of Swiss National Television “Eccellenze Ticinesi”
2021 – Advanced Biomaterial Research
Breakthroughs in polymer-nanoparticle hydrogels and nanomatrix biomatrices for controlled drug delivery.
InkVivo is awarded the BoldBrain Startup Challenge
2019 – First publication
Published “Universal Nanocarrier Ink Platform for Biomaterials Additive Manufacturing” in Small.
2017 – Begin of research
Research activities start as part of Elia Guzzi’s PhD.
Team
Meet the people driving innovation at InkVivo across our locations in Switzerland.
Headquarters
InkVivo Technologies AG
Piazza Cioccaro 4
6900 Lugano
Switzerland
Laboratory
InkVivo Technologies AG
c/o Macromolecular Lab, ETHZ
Sonneggstrasse 3
8006 Zürich
Switzerland
Elia Guzzi, Dr.
Co-Founder, CEO
PhD Biomedical Eng. ETHZ
Stefano Cerutti
Co-Founder, COO
EMBA HEC Lausanne
Leonardo Tognola
Co-Founder, CTO
MSc Mechanical Eng. ETHZ
Frantisek Surman, Dr.
Formulation Engineer
PhD Macromolecular Chemistry VSCHT
Pornpimol (Kuk) Scheuchzer, Dr.
Translational Scientist
PhD Food Eng. ETHZ
Team
Meet the people driving innovation at InkVivo across our locations in Switzerland.
Headquarters
InkVivo Technologies AG
Piazza Cioccaro 4
6900 Lugano
Switzerland
Laboratory
InkVivo Technologies AG
c/o Macromolecular Lab, ETHZ
Sonneggstrasse 3
8006 Zürich
Switzerland
Elia Guzzi, Dr.
Co-Founder, CEO
PhD Biomedical Eng. ETHZ
Leonardo Tognola
Co-Founder, CTO
MSc Mechanical Eng. ETHZ
Pornpimol_Scheuchzer
Translational Scientist
PhD Food Eng. ETHZ
Stefano Cerutti
Co-Founder, COO
EMBA HEC Lausanne
Frantisek Surman
Formulation Engineer
PhD Macromolecular Chemistry VSCHT
Board of Directors
Meet our Board
InkVivo Technologies AG
Elia Guzzi, Dr.
President of the Board
Lorenzo Leoni, Dr.
Member of the Boad
TiVentures SA
Stefano Cerutti
Member of the Board
Marco Ziegler, Dr.
Member of the Board
Claves Investment